Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK's house dust mite tablet in young children
Primary and all key secondary confirmatory endpoints were met, with an improvement in the total combined allergic rhinitis score of 22% compared to placebo . Results were highly statistically... | June 8, 2023